| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_751430a32763964dbc7195a2d58cffbc |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-644
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-644
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2018-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bbea4074c3e34df91daeaaaea565e45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e50ccfd141f258eb9807c2af6fb9a32d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d6591b4d24e0c6396283eb5a16164f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc81de5d3de31039fe9e6660a01f458e |
| publicationDate |
2018-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018221420-A1 |
| titleOfInvention |
Method to Suppress the Systemic Toxicity of Chemotherapeutic Drugs |
| abstract |
This invention relates to the combination of manuka honey with other chemotherapeutic agents to treat cancer and reduce the toxicity of the treatment. The invention relates also to an intravenous pharmaceutical composition comprising a diluent; at least 50% w/v of manuka honey diluted by the diluent; and at least one chemotherapeutic agent selected from the group consisting of paclitaxel 5 mg/kg of a patient to be treated; paclitaxel 8 mg/kg of a patient to be treated; oxaliplatin 6 mg/kg of a patient to be treated; and any pharmaceutically acceptable salts thereof. The invention relates further to a method of treating skin cancer, colon cancer, colorectal cancer and/or breast cancer in a patient comprising administering the intravenous pharmaceutical composition to the patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021002763-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2020299505-B2 |
| priorityDate |
2013-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |